Dietmar Berger

Chief Medical Officer, Gilead Sciences

Dietmar Berger, MD, PhD, is Chief Medical Officer and Executive Vice President at Gilead, responsible for the company’s leading virology, oncology and inflammation pipeline, as well as its global Development and Medical Affairs organizations. Together with the Gilead Leadership Team, he works to advance clinical development strategies and programs with the goals of changing the trajectory of disease and transforming care for patients and communities around the world.

Dietmar is a board-certified internist, hematologist and oncologist with more than 25 years of extensive experience in developing and delivering innovative medicines across a broad range of therapeutic areas. He joined Gilead in 2025 after serving as Senior Vice President, CMO and Global Head of Development at Sanofi, where he led clinical development for therapeutic areas that included immunology, hematology, oncology, neuroscience, rare diseases, diabetes and cardiovascular medicine. Prior to Sanofi, Dietmar served as Executive Vice President and Global Head of Research & Development at Atara Biotherapeutics Inc., as well as development and medical affairs roles at Genentech Inc., Bayer Healthcare Pharmaceuticals Inc. and Amgen Inc. He is Professor of Medicine at the University of Freiburg Hospital in Freiburg, Germany.

Dr. Berger completed his medical training in Freiburg (Germany), Basel (Switzerland) and Chicago (United States) and holds a MD and PhD from the Albert-Ludwigs University School of Medicine.

Chief Medical Officer, Global Head of Development, Sanofi

Dietmar Berger is Chief Medical Officer and Head of Global Development at Sanofi. In this role, Dr. Berger leads global development science, strategy and operations for the company’s portfolio in Immunology, Hematology, Oncology, Rare Diseases, and Neurology, and oversees pharmacovigilance and medical centers of excellence. Formerly, he was Senior Vice President of Global Product Development, Clinical Science Hematology/Oncology at Genentech/Roche, and Head of Research and Development at Atara, focusing on development of T cell immunotherapies. Prior to that, he held positions of increasing responsibility at Bayer and at Amgen.

Dr. Berger completed his medical training in Freiburg (Germany), Basel (Switzerland) and Chicago (United States) and holds an M.D. and Ph.D. from the Albert-Ludwigs University School of Medicine. He has more than 25 years of experience in oncology research and development, including as Head of the Clinical Research Center at the University Medical Hospital, Freiburg, Germany. Dr. Berger has led academic research groups focusing on preclinical drug development, tumor models, angiogenesis, and immunotherapy in Germany, and at The Scripps Research Institute, La Jolla, CA, USA. He received the Cancer Award of the German Cancer Society for his research on angiogenesis and has authored more than 50 scientific publications and five books.